Studies | N (total) | n (ULT) | Population, country | Age, yrs, mean (SD) | Male,(%) | Disease duration, yrs, mean (SD) | Medications | Quality |
Prescription claims | ||||||||
Sarawate et al, 200617 | 5942 | 2405 | Managed care database, USA | 57.4 (14.1)* | 76.4* | NS | Allopurinol | 4 |
Briesacher et al, 200818 | 9715 | MEDSTAT database, USA | 58.7 (0.14) | 77.5 | NS | Allopurinol, uricosurics | 4 | |
Harrold et al, 200924 | 4166 | Integrated delivery Systems, USA | 62 (14) | 75 | NS | Allopurinol, probenecid, sulfinpyrazone | 4 | |
Halpern et al, 200930 | 18 243 | 10 070 | Claims database, USA | Mean 53.9 | 84.2 | NS | Allopurinol | 4 |
Rashid et al, 201229 | 9288 | KPSC healthcare, USA | Mean 60 | 78 | NS | Allopurinol | 4 | |
Horsburgh et al, 201419 | 27 243 | 732 | Community pharmacy dispensing databases, New Zealand | NA | 39.5† | NS | Allopurinol | 4 |
Singh, 201423 | 43 | Outpatient clinic, USA | 63.9 (9.9) | 67 | NS | Allopurinol, febuxostat | 2 | |
McGowan et al, 201622 | 34 634 | 15 908 | HSE-PCRS scheme database, Ireland | Mean 65.2* | 73* | NS | Allopurinol, febuxostat, probenecid, sulfinpyrazone | 3 |
Tan et al, 201632 | 91 | Hospital clinics, Singapore | 53.5 (16.9) | 92.3 | NS | Allopurinol, probenecid | 2 | |
Solomon et al, 200821 | 9823 | Medicare and PACE enrollees, USA | Mean 79 | 28† | NS | Allopurinol | 4 | |
Park et al, 201226 | 352 | 242 | Scott & White Health Plan, USA | 61.02 (15.33)* | 72.4*† | NS | Allopurinol, febuxostat, probenecid | 4 |
Zandman-Goddard et al, 201320 | 7644 | MHS database, Israel | NA | 72 | NS | Allopurinol | 4 | |
Mantarro et al, 201531 | 3727 | HSD database, Italy | Mean 65 | 80 | NS | Allopurinol | 4 | |
Rashid et al, 201527 | 8288 | Clinical and administrative databases, USA | NA | 79.80 | NS | Allopurinol, febuxostat, probenecid | 4 | |
Kuo et al, 201528 | 49 395 | GPRD database, UK | NA | NA | NS | ULT | 4 | |
Riedel et al, 200425 | 9482 | 5597 | IPA plans, USA | 51(11)* | 82.1* | NS | Allopurinol | 4 |
Pill counts | ||||||||
Lee et al, 201633 | 132 | Outpatient clinic, Korea | 51.9 (10.4) | 100 | 100.0 (89.1)‡ | Allopurinol, febuxostat | 2 | |
Self-report | ||||||||
Silva et al, 201035 | 34 | Outpatient, Spain | 57.1 (11.8) | 94.1† | NS | Allopurinol, benzbromarone | 1 | |
Singh et al, 201634 | 499 | 251 | People visiting the Gout and Uric Acid Education Society’s website, USA | 56.3 (12.6)* | 73.7* | NS | Allopurinol, febuxostat | 5 |
Interview | ||||||||
Martini et al, 201236 | 60 | 56 | Community pharmacies, New Zealand | Mean 61* | 90* | NS | Allopurinol | 2 |
Sheng et al, 201438 | 161 | 80† | Gout Clinic, China | NA | NA | NS | ULD | 1 |
van Onna et al, 201537 | 15 | 12 | Outpatient clinic and primary care practices, The Netherlands | 63 (12)* | 93.3*† | 11(7)* | ULT | 2 |
*Data for total population.
†Calculated based on data provided in the article.
‡Disease duration (months).
cross, cross-sectional; NA, not applicable; NS, not stated; ULD, urate-lowering drugs; ULT, urate-lowering therapy; yr, year.